|
|
||||||||||
|
J Am Coll Cardiol, 2007; 49:2003-2009, doi:10.1016/j.jacc.2007.01.083
(Published online 3 May 2007). © 2007 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Veterans Affairs Boston Healthcare System, West Roxbury Campus, Brigham and Womens Hospital, and Harvard Medical School, Boston, Massachusetts.
Manuscript received January 19, 2006; revised manuscript received December 19, 2006, accepted January 3, 2007.
* Reprint requests and correspondence: Dr. Scott Kinlay, Cardiovascular Division, VA Boston Healthcare System, 1400 VFW Parkway, West Roxbury, Massachusetts 02132. (Email: skinlay{at}partners.org).
Objectives: This study sought to assess the contribution of low-density lipoprotein (LDL)dependent and LDLindependent effects of LDL-lowering therapies to changes in C-reactive protein (CRP) in healthy or stable subjects.
Background: Correlations of change in LDL and CRP in individuals are lowered by their measurement variability. By using average changes in LDL and CRP in study groups, meta-analysis reduces this variability to better assess their correlation.
Methods: A systematic search for randomized placebo-controlled trials reporting change in LDL and CRP with LDL-lowering interventions retrieved 23 studies with 57 groups treated with a variety of statins, nonstatin drugs, or other regimens. Meta-analysis techniques assessed the relationships between average mean differences (placebo treatment) in change in CRP and LDL.
Results: The overall reduction in CRP was 28% (95% confidence interval 26% to 30%). Significantly greater CRP reduction occurred in statin and statin-ezetimibe interventions, interventions using 80 mg/day of statins, and with greater LDL lowering. Meta-regression analysis showed a strong correlation between the change in LDL and CRP (r = 0.80, p < 0.001). Statin therapies had no significant effect on CRP after adjusting for the change in LDL. In a multivariate model applied to a range of LDL reduction typically seen with statins (20% to 60%), 89% to 98% of CRP change was related to LDL lowering and 2% to 11% was related to non-LDL effects of statins.
Conclusions: In clinical practice, most of the anti-inflammatory effect of LDL-lowering therapies is related to the magnitude of change in LDL. The potential non-LDL effects of statins on inflammation are much smaller in magnitude.
| |||||
This article has been cited by other articles:
![]() |
T. B. Grammer, W. Marz, W. Renner, B. O. Bohm, and M. M. Hoffmann C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study Eur. Heart J., May 21, 2008; (2008) ehn191v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al. Highlights of the year in JACC 2007. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512. [Full Text] [PDF] |
||||
![]() |
O. Ben-Yehuda High-Sensitivity C-Reactive Protein in Every Chart?: The Use of Biomarkers in Individual Patients J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2139 - 2141. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Tuzcu and S. J. Nicholls Statins: Targeting Inflammation by Lowering Low-Density Lipoprotein? J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2010 - 2012. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |